|
|
3100 Wilcrest Drive, Suite 140
Houston, TX 77042 USA
phone:(713) 789-0070
fax:(713) 789-0702
|
|
| Symbol |
CYGX |
| Exchange |
.OB |
| Founded |
0 |
| Employees |
|
|
|
| www.cytogenix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biopharmaceutical compounds and services based on gene regulating technology. |
|
| Management |
| Malcolm Skolnick, PhD, JD Chairman/President and CEO; Yin Chen, PhD Vice-president of Research & Development; Kurt L. Berens Vice-president of Product Development; Xin-Xing Tan, PhD - Senior Research Scientist; Harilyn McMicken, BS, MT(ASCP) Senior Laboratory Director; Frederic Kendirgi, PhD Research Scientist; Cindee Ewell, PhD, JD In House Counsel |
| |
|
|
|
|
|
|
|
| Keywords |
| herpes, alopecia, psoriasis, contact dermatitis, skin, gene, sepsis |
|
|
|
| Description |
|
CytoGenix, Inc., is developing biopharmaceutical compounds and services based on its proprietary gene regulating technology. They control U.S. and foreign patents for a technology that is effective in targeting and reducing gene expression. They have applied this technology to the development of anti-bacterial agents against sepsis, and topical compounds for the treatment of skin diseases and disorders such as, herpes, alopecia, psoriasis, and contact dermatitis.
CytoGenix core technology involves the harnessing of genetic mechanisms to instruct target cells to make multiple copies of single strand DNA or oligodeoxynucleotides (ODN's) in their cytoplasm. These small pieces of DNA can act in several ways to prevent errand genes from producing proteins. Individual ODN sequences can be coded to interrupt pre- and post-transcription or pre- and post-translation events. Depending on the gene target, ODN's can be coded to form anti-sense, DNA enzymes, triplex-forming or protein-binding pieces of ssDNA. Several of these techniques are employed in the Company's products.
CytoGenix is developing therapeutic products against infectious diseases, inflammatory disorders and Cancer. The Company is also engaged in the development of technology designed to deliver nucleic acids safely to targeted cells. |
|
| Products / Services |
Cytogenix patented intracellular ssDNA expression system has been shown to be highly effective in down regulating target gene expression. This technology has been used by investigators in in vitro and in vivo experiments. When transfected into cells, catalytic DNA generated by a CytoGenix proprietary vector inhibits target gene expression.
|
|
| Technology / Differentiation |
| CytoGenix proprietary technology interrupts the translation of mRNA.This occurs through a method of introducing specific DNA instructions that direct the cell's machinery to cancel translation of the mRNA of a specified gene into a protein. By harnessing the cell's natural internal DNA machinery to replicate the gene blocking instructions, this technology overcomes the limitation of other gene medicine approaches that require the introduction of large concentrations of DNA into the cells from external sources. |
|
| Market / Customers |
This technology enables and enhances the performance of gene medicine methods such as antisense and triplex.This technology also has great promise as a platform for the recently discovered DNA enzyme method.This fundamental molecular control in cells has the potential to be widely applied for the development of therapeutic agents against certain cancers, autoimmune and infectious diseases.The Company is developing various therapeutic products for diseases of the skin.The Company intends to seek licensees for other disease targets.
|
|
| Funding |
| The Company actively seeks funding from the federal government for scientific research and develops collaborative relationships with academic investigators whose scientific interests complement our goals. The federal government has programs designed to encourage these collaborations.
The National Institute of Child Health/Human Development (NICHD) has awarded the Company a Small Business Technology Transfer Program (STTR) Grant entitled, "ssDNA Expression of Triplex-Forming Oligonucleotides". The first phase of funding of $100,000 will support Cancer research conducted by Dr. Peter Glazer at Yale University and by Dr. Chen in the CytoGenix laboratory.
The National Cancer Institute (NCI) has awarded a Small Business Innovation Research (SBIR) to fund $100,000 for the first phase of a project titled: "PEI Aerosol Delivery of ssDNA Expression Vector." This an aerosol compound containing the Company's single stranded DNA vector coded with an anti-cancer gene sequence will be tested on mice with induced tumors in their lungs. Positive results will lead the way to further animal studies and eventually human trials. Dr. Charles Densmore at Baylor College of Medicine, Houston and Dr. Yin Chen at CytoGenix are conducting this research. |
|
| Status |
| The Company's research and development projects will result in clinically testable products. In addition to their anti-herpes and anti-microbial products, CytoGenix will complete studies on their anti-inflammatory product, CY302, and submit the pre-IND briefing document to the FDA. They expect to have two and perhaps, three products in clinical trials next year. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
